NYSE:ACB (Canada) Also trade in: Canada Germany UK

Aurora Cannabis Inc

$ 8.62 -0.04 (-0.46%)
Volume: 5,945,657 Avg Vol (1m): 27,878,894
Market Cap $: 8.71 Bil Enterprise Value $: 8.79 Bil
P/E (TTM): 0.00 P/B: 2.72
Earnings Power Value -0.57
Net Current Asset Value -0.25
Tangible Book 0.37
Projected FCF 1.72
Median P/S Value 4.13
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.84
Cash-To-Debt ranked lower than
55.18% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
ACB: 0.84
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 10000, Max: 10000
Current: 0.84
0.02
10000
Equity-to-Asset 0.79
Equity-to-Asset ranked higher than
80.08% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
ACB: 0.79
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.32, Med: 0.78, Max: 1
Current: 0.79
0.32
1
Debt-to-Equity 0.15
Debt-to-Equity ranked higher than
68.46% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
ACB: 0.15
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.28, Max: 3.03
Current: 0.15
0
3.03
Debt-to-EBITDA -4.24
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
ACB: -4.24
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -4.29, Med: -1.01, Max: 2.21
Current: -4.24
-4.29
2.21
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.07
DISTRESS
GREY
SAFE
Beneish M-Score 0.38
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -7.48%
WACC 13.83%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -167.12
Operating Margin ranked lower than
84.39% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
ACB: -167.12
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -318.97, Med: -142.6, Max: -53.36
Current: -167.12
-318.97
-53.36
Net Margin % -123.68
Net Margin ranked lower than
78.55% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
ACB: -123.68
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -397.71, Med: -71.78, Max: 130.33
Current: -123.68
-397.71
130.33
ROE % -6.58
ROE ranked lower than
67.07% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
ACB: -6.58
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -339.81, Med: -22.02, Max: 8.09
Current: -6.58
-339.81
8.09
ROA % -5.56
ROA ranked lower than
65.56% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
ACB: -5.56
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -100.09, Med: -21.61, Max: 6.44
Current: -5.56
-100.09
6.44
ROC (Joel Greenblatt) % -49.46
ROC (Joel Greenblatt) ranked lower than
69.82% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
ACB: -49.46
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -33100, Med: -118.69, Max: 54.55
Current: -49.46
-33100
54.55

» ACB's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14 Est.)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:ACB

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325411    SIC : 3741
Compare HKSE:03320 SHSE:600332 TSE:4506 XSWX:VIFN XPAR:IPN OCSE:LUN TSX:BHC SHSE:600196 SHSE:600518 SZSE:300122 TSE:4581 SZSE:000963 TSE:4508 NYSE:PRGO NSE:AUROPHARMA BOM:500124 NYSE:CTLT NSE:DIVISLAB NYSE:ELAN OSTO:SOBI
Traded in other countries 21P.Germany 0UJG.UK
Address 10355 Jasper Avenue, Suite 500, Edmonton, AB, CAN, T5J 1Y6
Aurora Cannabis Inc is involved in the business of production and distribution of Marijuana. The firm's product portfolio includes Cannabis oil. Dried cannabis and Milled blend. It has categorized its products in Indica, Sativa and Hybrid types. The company has Production and sale of medical cannabis operating segment. It generates all of its revenues in Canada.

Ratios

Current vs industry vs history
PB Ratio 2.72
PB Ratio ranked higher than
53.72% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
ACB: 2.72
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.26, Med: 1.05, Max: 19.18
Current: 2.72
0.26
19.18
PS Ratio 62.56
PS Ratio ranked lower than
93.16% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
ACB: 62.56
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 7.5, Med: 30, Max: 295
Current: 62.56
7.5
295
EV-to-EBIT -52.32
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
ACB: -52.32
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -486.8, Med: 0.9, Max: 498.2
Current: -52.32
-486.8
498.2
EV-to-EBITDA -80.59
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
ACB: -80.59
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -711.4, Med: 0.9, Max: 411.4
Current: -80.59
-711.4
411.4
EV-to-Revenue 71.29
EV-to-Revenue ranked lower than
94.72% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
ACB: 71.29
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -22.4, Med: 2.5, Max: 435.6
Current: 71.29
-22.4
435.6
Current Ratio 2.37
Current Ratio ranked higher than
85.61% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
ACB: 2.37
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.14, Med: 29.71, Max: 1754
Current: 2.37
0.14
1754
Quick Ratio 2.13
Quick Ratio ranked higher than
85.73% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
ACB: 2.13
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.11, Med: 29.15, Max: 1754
Current: 2.13
0.11
1754
Days Inventory 363.46
Days Inventory ranked lower than
97.88% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
ACB: 363.46
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 363.46, Med: 582.93, Max: 909.32
Current: 363.46
363.46
909.32
Days Sales Outstanding 114.60
Days Sales Outstanding ranked higher than
57.53% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
ACB: 114.6
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 21.31, Med: 27.19, Max: 114.6
Current: 114.6
21.31
114.6
Days Payable 577.25
Days Payable ranked lower than
98.68% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
ACB: 577.25
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 577.25, Med: 1483.38, Max: 1588.68
Current: 577.25
577.25
1588.68

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -68.50
3-Year Share Buyback Rate ranked lower than
95.10% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
ACB: -68.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -143, Med: -68.5, Max: -0.3
Current: -68.5
-143
-0.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 23.30
Price-to-Tangible-Book ranked lower than
80.64% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
ACB: 23.3
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.35, Med: 1.54, Max: 23.68
Current: 23.3
0.35
23.68
Price-to-Projected-FCF 5.01
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
74.06% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
ACB: 5.01
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0, Med: 4, Max: 57.5
Current: 5.01
0
57.5
Price-to-Median-PS-Value 2.09
Price-to-Median-PS-Value ranked lower than
88.69% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
ACB: 2.09
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0, Med: 1.57, Max: 9
Current: 2.09
0
9
Earnings Yield (Joel Greenblatt) % -1.90
Earnings Yield (Greenblatt) ranked lower than
66.78% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
ACB: -1.9
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -136.4, Med: 1.5, Max: 1173.3
Current: -1.9
-136.4
1173.3

More Statistics

Revenue (TTM) (Mil) $ 128.15
EPS (TTM) $ -0.08
Beta 2.62
Volatility % 82.93
52-Week Range $ 4.05 - 12.53
Shares Outstanding (Mil) 1,012.59

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N